Russell Schundler Sells 27,289 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 27,289 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the sale, the general counsel owned 579,394 shares in the company, valued at approximately $21,686,717.42. This represents a 4.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Monday, December 1st, Russell Schundler sold 1,072 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total transaction of $34,507.68.

Liquidia Price Performance

Shares of Liquidia stock opened at $39.99 on Thursday. The firm has a market cap of $3.48 billion, a PE ratio of -27.77, a P/E/G ratio of 0.65 and a beta of 0.48. The business has a 50-day moving average price of $32.41 and a 200 day moving average price of $25.68. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. Liquidia Corporation has a twelve month low of $11.26 and a twelve month high of $40.53.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The company had revenue of $54.34 million during the quarter, compared to analyst estimates of $18.86 million. The company’s revenue was up 1106.7% on a year-over-year basis. Sell-side analysts predict that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent patent and court wins reduce execution and IP risk for Liquidia’s inhaled treprostinil program, supporting upside potential for commercialization. Seeking Alpha – Patent Update
• Positive Sentiment: Analyst sentiment has been upgraded recently (multiple firms raising targets and issuing Buy/Strong Buy ratings), which can attract fresh capital and lend support to the rally. Benzinga – Analyst Expectations
• Positive Sentiment: Short interest fell materially in December (reported ~18% decline), lowering potential downward pressure from short sellers and reducing immediate squeeze/volatility risk. MarketBeat – Short Interest & Court Coverage
• Neutral Sentiment: Analyst/industry write-ups note the company has won many patent battles but caution the “war is not yet won,” signaling that legal/IP progress is positive but some uncertainties remain. Seeking Alpha – Balanced Take
• Negative Sentiment: Large, coordinated insider selling occurred on Jan. 12: CEO Roger Jeffs (66,610 sh, ~$2.49M), CFO Michael Kaseta (36,932 sh, ~$1.38M), General Counsel Russell Schundler (27,289 sh, ~$1.02M) and several other insiders (collectively selling millions of dollars of stock). While insiders still retain significant stakes, the volume and scale of sales may be viewed as profit‑taking and can weigh on sentiment. MarketBeat – Insider Trades

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares during the period. Rhumbline Advisers increased its stake in Liquidia by 6.0% during the first quarter. Rhumbline Advisers now owns 85,463 shares of the company’s stock worth $1,261,000 after purchasing an additional 4,811 shares during the period. Finally, Ballentine Partners LLC lifted its position in shares of Liquidia by 10.2% during the second quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock worth $151,000 after purchasing an additional 1,119 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LQDA has been the subject of a number of recent research reports. BTIG Research reiterated a “buy” rating and issued a $49.00 target price on shares of Liquidia in a research report on Friday, January 9th. Wells Fargo & Company started coverage on Liquidia in a research note on Monday, October 20th. They set an “overweight” rating and a $31.00 price objective on the stock. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Raymond James Financial reiterated a “strong-buy” rating and issued a $47.00 price objective on shares of Liquidia in a report on Tuesday, November 4th. Finally, Needham & Company LLC raised their target price on Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).